Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,930 DKK | -0.54% | -0.36% | -10.44% |
06-04 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.44% | 17.96B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B | |
+83.45% | 9.17B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S, Q1 2022 Earnings Call, May 11, 2022